InMed Pharmaceuticals (INM) Invested Capital (2021 - 2025)
InMed Pharmaceuticals' Invested Capital history spans 5 years, with the latest figure at $9.6 million for Q4 2025.
- For Q4 2025, Invested Capital rose 55.09% year-over-year to $9.6 million; the TTM value through Dec 2025 reached $9.6 million, up 55.09%, while the annual FY2025 figure was $13.4 million, 45.93% up from the prior year.
- Invested Capital reached $9.6 million in Q4 2025 per INM's latest filing, down from $11.6 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $15.2 million in Q3 2021 to a low of -$9.6 million in Q3 2023.
- Average Invested Capital over 5 years is $9.9 million, with a median of $11.1 million recorded in 2022.
- Peak YoY movement for Invested Capital: tumbled 187.01% in 2023, then soared 187.65% in 2024.
- A 5-year view of Invested Capital shows it stood at $14.2 million in 2021, then increased by 0.77% to $14.3 million in 2022, then dropped by 10.9% to $12.8 million in 2023, then crashed by 51.6% to $6.2 million in 2024, then skyrocketed by 55.09% to $9.6 million in 2025.
- Per Business Quant, the three most recent readings for INM's Invested Capital are $9.6 million (Q4 2025), $11.6 million (Q3 2025), and $13.4 million (Q2 2025).